"Ganciclovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
MeSH Number(s)
D03.438.759.758.399.454.250.300
Below are MeSH descriptors whose meaning is more general than "Ganciclovir".
Below are MeSH descriptors whose meaning is more specific than "Ganciclovir".
This graph shows the total number of publications written about "Ganciclovir" by people in Harvard Catalyst Profiles by year, and whether "Ganciclovir" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 4 | 5 | 9 |
1995 | 5 | 1 | 6 |
1996 | 8 | 3 | 11 |
1997 | 6 | 4 | 10 |
1998 | 8 | 4 | 12 |
1999 | 2 | 7 | 9 |
2000 | 8 | 5 | 13 |
2001 | 5 | 5 | 10 |
2002 | 4 | 2 | 6 |
2003 | 2 | 3 | 5 |
2004 | 2 | 5 | 7 |
2005 | 1 | 1 | 2 |
2006 | 2 | 3 | 5 |
2007 | 0 | 5 | 5 |
2008 | 1 | 1 | 2 |
2009 | 2 | 4 | 6 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2013 | 1 | 8 | 9 |
2014 | 2 | 2 | 4 |
2015 | 1 | 0 | 1 |
2016 | 1 | 3 | 4 |
2017 | 1 | 1 | 2 |
2018 | 1 | 1 | 2 |
2019 | 1 | 2 | 3 |
2020 | 0 | 1 | 1 |
2021 | 1 | 1 | 2 |
2022 | 0 | 2 | 2 |
2023 | 0 | 4 | 4 |
2024 | 0 | 1 | 1 |
Below are the most recent publications written about "Ganciclovir" by people in Profiles.
-
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J Infect Dis. 2024 Feb 14; 229(2):413-421.
-
Developing and characterizing a two-layered safety switch for cell therapies. Cancer Biol Ther. 2023 12 31; 24(1):2232146.
-
Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients. Am J Transplant. 2023 Dec; 23(12):1961-1971.
-
The Infectious Uveitis Treatment Algorithm Network (TITAN) Report 2-global current practice patterns for the management of Cytomegalovirus anterior uveitis. Eye (Lond). 2024 01; 38(1):68-75.
-
The Best Method for CMV Prevention in High-risk Kidney Transplant Recipients? Either, per National Norwegian Transplant Database: Commentary on Blom et al, Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management. Transplantation. 2023 08 01; 107(8):1671-1672.
-
Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. J Infect Dis. 2022 09 04; 226(4):576-584.
-
Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nat Biotechnol. 2022 07; 40(7):1103-1113.
-
Cytomegalovirus skin disease in a kidney transplant patient. BMJ Case Rep. 2021 Jul 05; 14(7).
-
CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. J Clin Invest. 2021 01 04; 131(1).
-
PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2020 11 01; 80(21):4731-4740.